- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Time, Money Worry Healthcare CIOs in Stage 2 Meaningful Use
According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.
For eligible hospitals (EHs), the next phase of the EHR Incentive Programs (i.e., Stage 2 Meaningful Use) begins in October. According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.
The Implementation Workgroup, a subcommittee of the Health Information Technology Standards Committee (HITSC), held an all-day hearing featuring four panels, two of which dealing with the challenges facing eligible providers preparing for Stage 2 Meaningful Use.
During the third panel of the Implementation and Usability Hearing, a select panel of healthcare CIOs gave testimony in response to questions posed by the HITSC workgroup. Considering the number of mandates and initiatives hospitals are facing in the coming use, a common theme emerged among the panelists: Many hospitals lack both the time and money to keep pace with meaningful use on top of their other responsibilities.
Read the full story: http://bit.ly/13DXJNv
Source: EHR Intelligence
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
